CAPR
Capricor Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.40
+1.29%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 22.3M | 25.2M | 2.6M |
| Cost of Revenue | 20.4M | — | 50.0M | 36.4M | 21.8M |
| Gross Profit | (20.4M) | — | (27.7M) | (11.3M) | (19.3M) |
| Operating Expenses | |||||
| R&D Expense | 99.7M | 84.5M | 50.0M | 36.4M | 21.8M |
| SG&A Expense | 35.2M | 22.7M | 14.9M | 12.8M | 10.4M |
| General & Admin Expense | 29.1M | 22.7M | 14.9M | 12.8M | 10.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (20.1M) | 938.9K | (50.0M) | (36.4M) | (21.8M) |
| Total Operating Expenses | 114.8M | 108.1M | 14.9M | 12.8M | 10.4M |
| Cost and Expenses | 135.2M | 108.1M | 64.8M | 49.3M | 32.2M |
| Operating Income (EBIT) | (135.2M) | (108.1M) | (42.6M) | (24.1M) | (29.7M) |
| Non-Operating | |||||
| Interest Income | 8.9M | 6.3M | 2.2M | 1.7M | 521.5K |
| Interest Expense | 3.0M | 3.0M | — | — | — |
| Net Interest Income | 5.8M | 3.2M | 2.2M | 1.7M | 521.5K |
| Other Non-Op Income/Expense | 5.7M | 3.1M | 2.1M | 1.8M | 677.9K |
| Non-Operating Income (excl Interest) | (8.8M) | (6.1M) | (2.1M) | (1.8M) | (677.9K) |
| EBT (Pre-Tax Income) | (129.4M) | (105.0M) | (40.5M) | (22.3M) | (29.0M) |
| Income Tax Expense | 1.6K | — | — | — | — |
| Bottom Line | |||||
| Net Income | (129.4M) | (105.0M) | (40.5M) | (22.3M) | (29.0M) |
| Earnings from Cont. Ops | (129.4M) | (105.0M) | (40.5M) | (22.3M) | (29.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (129.4M) | (105.0M) | (40.5M) | (22.3M) | (29.0M) |
| Per Share | |||||
| Basic EPS | ($2.45) | ($2.26) | ($1.15) | ($0.83) | ($1.18) |
| Diluted EPS | ($2.45) | ($2.26) | ($1.15) | ($0.83) | ($1.18) |
| Revenue Per Share | $0.00 | $0.00 | $0.63 | $0.94 | $0.10 |
| Shares | |||||
| Basic Shares Outstanding | 57.9M | 46.5M | 35.2M | 26.8M | 24.6M |
| Diluted Shares Outstanding | 57.9M | 46.5M | 35.2M | 26.8M | 24.6M |
| Profitability Metrics | |||||
| EBITDA | 1.2B | (100.1M) | (39.0M) | (21.2M) | (28.5M) |
| D&A | 1.3B | 1.9M | 1.4M | 1.1M | 533.1K |
| EBIT | (126.4M) | (102.0M) | (40.5M) | (22.3M) | (29.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026